🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Este paper de una de nuestras grandes de ⭕️ redGDPS Diabetes, Ana Cebrián, es un "imperdible" si quieres estar a la última en #EnfermedadRenalCrónica y #DM2. Se acompaña además de un video explicativo muy recomendable que facilita profundizar en los puntos relevantes. American Diabetes Association

📌Routine screening in HFpEF patients reveals hidden conditions like sleep apnoea (33%) and iron deficiency (35%) on top of existing comorbidities. 🔍Conditions like diabetes and obesity were undertreated ✅Systematic checks=better detection+improved care shorturl.at/H5zfe

🔰iSGLT-2 sobre la función autonómica cardíaca en personas con y sin DM2 ( no dejan de sorprender) . ✅Los efectos hemodinámicos y metabólicos, efectos en la supresión de la inflamación sistémica y el estrés oxidativo, la promoción de una remodelación cardíaca favorable, la

Nuevo post en #blogdemateu con el comentario del Dr. joan barrot sobre el Consenso de la American Diabetes Association - DiabetesPro ⭕️ Enfermedad hepática esteatótica asociada a disfunción metabólica (MASLD) en personas con #DM : necesidad de detección e intervención temprana. redgedaps.blogspot.com/2025/07/enferm…

Muy buena imagen de los efectos del antagonismo de los receptores mineralocorticoides en glomérulo y corazón 🙌🏻🙌🏻 Finerenona

📌 Use of #tirzepatide / semaglutide 👉 assoc. w/ ⬇️ incidence of ✅ #dementia, ✅ #stroke ✅ all-cause #death 👉 in 👫 w/ both #diabetes & #obesity #CardioTwitter #MedTwitter The Heart CardiovascularCorner Dr. Martha Gulati ♥️🫀❤️‍🩹🇨🇦 Erin D. Michos, M.D. Dr Anastasia Mihailidou FAHA FCSANZ FESC Mauricio Gonzalez MD. Dr. Rahul Baxi

Finerenone: Will It Be a Game-changer? Its combination with therapies, such as sodium–glucose cotransporter 2 inhibitors, shows promise and ongoing trials, such as REDEFINE-HF, FINALITY-HF and CONFIRMATION-HF, are investigating its efficacy in other HF phenotypes. These

📚 Revisión de lectura obligatoria en Endocrine Reviews (2025): la resistencia a la insulina es frecuente en #DiabetesTipo1, incluso desde fases tempranas, y se asocia a mayor riesgo cardiovascular/renal/microvasc y peor control HbA1c. 🧠 Implicaciones clínicas y terapéuticas

🧬 ¿GLP-1 ya no basta, es obsoleto este concepto? La revolución farmacológica en diabetes y obesidad superó al GLP-1. Este artículo en Lancet Diabetes Endocrinology propone una nueva nomenclatura. Te lo resumo en 3 puntos: 🧵 ¿TE SUBES A ESTE CARRO?

What is the influence of circadian rhythms on cardiovascular health in the context of specific cardiac diseases and risk factors? The answers in a State-of-the-Art review in #EHJ 👉 ow.ly/m0aC50WsruP Rocco Montone EHJ Editor-in-Chief

New content online: Balancing weight and muscle loss in GLP1 receptor agonist therapy bit.ly/41il6iv

🫀 Advanced heart disease in older adults raises tough questions: Are we helping, or just prolonging suffering? 👉 What’s your take on decision-making in these complex setting? #HeartFailure #Cardiology #Geriatrics

🔥 New study in AJPC: County-level extreme heat risk is tied to increased premature all-cause mortality linked to cardio-kidney-metabolic syndrome across the U.S. 🌡️🫀 Understand how rising temperatures are impacting public health. 🔗 sciencedirect.com/science/articl…

🔴🔴Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated CV protection in patients with type 2 diabetes and heart disease 👍Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater

❗️Tirzepatide meets primary and secondary outcomes in its CVOT (SURPASS-CVOT)❗️ 🔹A first for CVOTs - comparing to dulaglutide (established benefit) 🔸Statistical analysis allows for comparison to putative placebo 🔹1ry outcome HR 0.92 p=0.086 🔸2ndry outcome HR 0.84 0=0.002

Evaluation of Lipoprotein(a) as a Prognostic Marker of Extracoronary Atherosclerotic Vascular Disease Progression High concentrations of Lp(a) are associated with both incident extracoronary atherosclerotic vascular disease and progression to major complications

Lifetime CVD risk estimate is needed for younger people! 🫀 when incorporate PRS: prediction improves 🫀when you know PRE: can influence cascade screening 🫀We need earlier & more accurate assessment beyond risk scores #ASPC2025 Pradeep Natarajan

atherosclerosis-journal.com/article/S0021-…

Orgulloso de que el límite inferior de normalidad de #ferritina en HospitalUVRocio sea 30 ng/ml en ambos sexos, y pronto en toda la provincia de #Sevilla. Rethinking ferritin thresholds: towards a physiological-based definition of iron deficiency thelancet.com/journals/langl…

☝️LDL-C: No myths. No safe zone. 📉 Risk is proportional. 📉 The lower, the better. 📉 Regression starts at 50–70 mg/dL. 👉Lower LDL-C → Fewer events → Reversed disease. Not opinion. Science. European Atherosclerosis Society